GlassScriptPhysician profile
Douglas Skarada
NPI 1770588949
$6,616.80
in general payments reported to CMS, 2019-2025
11 companies · $95.48 in 2025
The $95.48 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $1,611 · 2021: $181 · 2022: $3,414 · 2023: $512 · 2024: $421 · 2025: $95.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,759.73 | 2021-2024 | Nuvent, Propel, Stealthstation S8 Platform |
| Medtronic USA, INC. | $1,756.46 | 2019-2020 | |
| Stryker Corporation | $1,554.45 | 2019-2025 | Scopis Ent, Audion Et Dilation System |
| Somnomed INC. | $302.00 | 2024 | |
| Aerin Medical INC. | $90.13 | 2019-2023 | |
| Kaleo, INC. | $58.37 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $37.44 | 2023 | Dupixent |
| Intersect Ent, INC. | $27.32 | 2020 | |
| Acclarent, INC | $13.90 | 2019 | |
| Optinose US, INC. | $11.50 | 2019 | |
| Xoran Technologies LLC | $5.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Skarada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.